Clinical study of RGN-259 for Dry Eye Disease
Latest Information Update: 31 Oct 2022
At a glance
- Drugs Timbetasin (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Diagnostic use
- Acronyms ARISE-4
- Sponsors ReGenTree
Most Recent Events
- 24 Oct 2022 According to a RegeneRx Biopharmaceuticals media release, this trial is expected to begin in Q2 2023.
- 24 Oct 2022 According to a RegeneRx Biopharmaceuticals media release, company submitted a request for the Special Protocol Assessment (SPA) to the U.S. FDA for an in-depth discussion and assessment of the clinical protocol for this trial.
- 29 Jun 2022 New trial record